Gifford Bioscience (formerly InvivoPharm Inc) is a preclinical contract research organization (CRO) providing services in receptor occupancy studies, radioligand binding assays and autoradiography.
We are a highly specialised company. This ensures that we have a deep experience in our assays, assuring our clients of the highest quality results.
In addition to undertaking standard or custom assays on a client’s sample to our client’s specification, our capabilities include assay design, in-house production of membrane preparations and, through our connection with the University of Birmingham, dosing in vivo or ex vivo and assays requiring human tissue samples.
We are based at the BioHub Birmingham.
CONTACT US for a chat. We are always happy to discuss potential requirements and assay design.
The Management Team
Dr Andrew Gifford
Chairman and Chief Scientific Officer
Andrew was previously a Senior Scientist in the radiopharmaceutical development program at Brookhaven National Laboratory, New York. As a Principal Investigator, he has been responsible for the preclinical development of a variety of radiolabelled drugs. Techniques employed in his academic laboratories were primarily radiometric ligand binding and occupancy assays, radiolabeling chemistry and autoradiography.
Andrew is a graduate of Imperial College, London and was awarded his PhD in Pharmacology by the University of St. Andrews.
Mr Macer Gifford
Macer is a banker by profession. His career has spanned numerous senior roles, including Deputy Group CEO at Ahli United and Group Head of Regional Markets at Standard Chartered.
Macer is a graduate of the London School of Economics and a Sloan Fellow of the London Business School.
Copyright 2008 – 2019 Gifford Bioscience Limited